Investigate / CAH
Understand CARDINAL HEALTH INC
Can growth in branded and specialty pharmaceuticals and acquired physician-services platforms be sustained while regulatory scrutiny and an acquisition-related impairment are managed?
Snapshot reviewed 2026-10-02. Source published 2026-08-11. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / CAH
Ask better questions. Keep the evidence.
Explore the available sources for CARDINAL HEALTH INC, then keep what deserves another look.
01 Investor activity
Who reports owning CAH?
4 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Cardinal Health provides pharmaceuticals, medical products and healthcare services to hospitals, pharmacies, surgery centers, laboratories, physician offices and patients at home.
Latticework interpretation
What could support the case?
If contributions from pharmaceuticals, generics and acquired platforms continue, those areas could support adjusted operating earnings, a non-GAAP measure.
Latticework interpretation
What could break the case?
If government investigations or false-claims actions result in sanctions, Cardinal Health could lose licenses or access to government healthcare programs.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Cardinal Health provides pharmaceuticals, medical products and healthcare services to hospitals, pharmacies, surgery centers, laboratories, physician offices and patients at home.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-K, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Full year: 2025-07-01–2026-06-30; prior 2024-07-01–2025-06-30Both values reported in the current filing. | $254,248m | $222,578m |
| Operating income ↗Full year: 2025-07-01–2026-06-30; prior 2024-07-01–2025-06-30Both values reported in the current filing. | $2,613m | $2,275m |
| Net income ↗Full year: 2025-07-01–2026-06-30; prior 2024-07-01–2025-06-30Both values reported in the current filing. | $1,714m | $1,561m |
| Operating cash flow ↗Full year: 2025-07-01–2026-06-30; prior 2024-07-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $5,174m | $2,397m |
Comparison caveat: Cash flow reflects vendor-payment timing, working-capital changes and opioid-litigation payments; the prior year also includes the OptumRx unwind. It is not purely recurring earnings growth.
10-K · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If contributions from pharmaceuticals, generics and acquired platforms continue, those areas could support adjusted operating earnings, a non-GAAP measure.
Supporting filing ↗The strongest caution
If government investigations or false-claims actions result in sanctions, Cardinal Health could lose licenses or access to government healthcare programs.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How dependent are earnings on generic pharmaceutical conditions?
Starting evidence: Generic earnings are generally highest right after a product launch, because selling prices tend to decline over time.
Investigate next: Review how generics program contribution changes as products age and how many new launches are expected.
Read the supporting filing ↗What explains the impairment in the oncology unit?
Starting evidence: A goodwill impairment was recognized for the Navista and Integrated Oncology Network reporting unit within the Pharma segment, partially offsetting operating earnings growth.
Investigate next: Read the goodwill note for the assumptions behind the impairment and for remaining goodwill in other acquired platforms.
Read the supporting filing ↗How might the government investigation develop?
Starting evidence: The company reports a Department of Justice investigation into potential healthcare-law violations relating to a purchasing-organization acquisition and rheumatology investment.
Investigate next: Check legal proceedings and contingencies notes for any estimated exposure, updates, or related disclosures.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.